抗生物質に対する非最適の微生物の反応が,抑制性薬物相互作用の根底にある
Tobias Bollenbach1, Selwyn Quan, Remy Chait
1Department of Systems Biology, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA.
Cell
|November 17, 2009
まとめ
抗生物質の相互作用は,細菌の成長を抑制することができます. この研究は,DNAのストレス下での非最適のリボソーム遺伝子調節がこれを引き起こし,それを修正することで細菌の生存と成長を改善することを明らかにしています.
科学分野:
- 微生物学 微生物学とは
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- 一つの抗生物質が他の抗生物質の存在で細菌の成長を促進する抑制性薬物相互作用は,タンパク質とDNA合成阻害剤の間で観察されています.
- これらの相互作用の根底にある遺伝的メカニズムは,まだ完全に理解されていません.
研究 の 目的:
- タンパク質とDNA合成を標的とする抗生物質間の抑制性薬物相互作用の遺伝的基礎を解明する.
- DNAストレスに対する細菌の反応におけるリボソーム遺伝子調節の役割を調査する.
主な方法:
- DNAストレス下でのリボソーム遺伝子発現を監視するために,Escherichia coliでGFPタグされたトランスクリプションレポーターを使用した.
- リボソームの遺伝子発現レベルを操作するために,リボソームのRNAオペロンの連続的な削除を行った.
- 観察された規制パターンを説明するための数学的モデルを開発した.
主要な成果:
- リボソーム遺伝子はDNAストレスによって直接制御されず,細胞のDNAとタンパク質の不均衡が生じます.
- リボソームの遺伝子発現を合成的に減少させ,不均衡を修正し,細菌の成長と生存を向上させた.
- これらの操作により,抑制性薬物相互作用の完全な除去が達成されました.
結論:
- DNAのストレス下でのリボソーム遺伝子の非最適の調節が抑制性薬物相互作用の原因である.
- リボソーム遺伝子の発現を調節することで,これらの抑制効果を克服し,細菌の健康状態を改善することができます.
- この研究は,抗生物質抑制相互作用を駆動する重要な遺伝的メカニズムを明らかにしています.
関連する概念動画
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
00:57Antibiotic Selection
Overview
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...